Cyclerion Therapeutics (CYCN) Capital Expenditures (2018 - 2023)
Cyclerion Therapeutics (CYCN) posted quarterly Capital Expenditures of -$31000.0 for Q3 2023, up 65.93% year-over-year from -$18682.1 in Q3 2022, and up 65.93% quarter-over-quarter from -$91000.0 in Q2 2023.
Cyclerion Therapeutics (CYCN) Capital Expenditures (2018 - 2023) Analysis & Trends
Cyclerion Therapeutics' Capital Expenditures history runs 6 years deep, the most recent figure standing at -$31000.0 for Q3 2023.
- In Q3 2023, Capital Expenditures rose 65.93% year-over-year to -$31000.0; the TTM figure through Jun 2024 stood at -$31000.0 (up 91.51% YoY), while the FY2023 annual figure was -$213000.0, up 41.8% from the prior year.
- Capital Expenditures for Q3 2023 stood at -$31000.0, up from -$91000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $812000.0 in Q2 2020, with the low at -$373000.0 in Q4 2021.
- The 5-year median for Capital Expenditures is -$61000.0 (2021), against an average of $60777.8.
- The sharpest annual moves came in 2020 and 2021: Capital Expenditures jumped 4373.68% in 2020, then plunged 333.33% in 2021.
- Cyclerion Therapeutics' Capital Expenditures stood at $540000.0 in 2019, then increased by 0.93% to $545000.0 in 2020, then tumbled by 168.44% to -$373000.0 in 2021, then jumped by 75.34% to -$92000.0 in 2022, then jumped by 66.3% to -$31000.0 in 2023.
- Business Quant data shows CYCN's Capital Expenditures at -$31000.0 in Q3 2023, -$91000.0 in Q2 2023, and -$91000.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Cyclerion Therapeutics | 12.71 Mn | 9.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | -31,000.00 |
| Sep 30, 2023 | -31,000.00 |
| Jun 30, 2023 | -91,000.00 |
| Jun 30, 2023 | -91,000.00 |
| Mar 31, 2023 | -91,000.00 |
| Mar 31, 2023 | -91,000.00 |
| Dec 31, 2022 | -92,000.00 |
| Dec 31, 2022 | -92,000.00 |
| Sep 30, 2022 | -91,000.00 |
| Sep 30, 2022 | -91,000.00 |
| Jun 30, 2022 | -92,000.00 |
| Jun 30, 2022 | -92,000.00 |
| Mar 31, 2022 | -91,000.00 |
| Mar 31, 2022 | -91,000.00 |
| Dec 31, 2021 | -373,000.00 |
| Dec 31, 2021 | -373,000.00 |
| Sep 30, 2021 | 190,000.00 |
| Sep 30, 2021 | 190,000.00 |
| Jun 30, 2021 | -92,000.00 |
| Jun 30, 2021 | -92,000.00 |